These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11321040)

  • 21. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
    Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
    Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.
    Ge F; Lu XP; Zeng HL; He QY; Xiong S; Jin L; He QY
    J Proteome Res; 2009 Jun; 8(6):3006-19. PubMed ID: 19364129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
    Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha.
    Minami R; Muta K; Ilseung C; Abe Y; Nishimura J; Nawata H
    Exp Hematol; 2000 Mar; 28(3):244-55. PubMed ID: 10720689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
    Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
    Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
    Anreddy N; Hazlehurst LA
    J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in therapeutic strategies for multiple myeloma].
    Miwa A
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2200-16. PubMed ID: 18079620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.
    Hideshima T; Mazitschek R; Santo L; Mimura N; Gorgun G; Richardson PG; Raje N; Anderson KC
    Leukemia; 2014 Feb; 28(2):457-60. PubMed ID: 24150220
    [No Abstract]   [Full Text] [Related]  

  • 34. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.
    Feng W; Fu Y; Zhang Y; Lv B; Li X; Zhang F; Gui R; Liu J
    Int J Clin Exp Pathol; 2015; 8(9):10635-43. PubMed ID: 26617773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation.
    Choi PJ; O Y; Her JH; Yun E; Song GY; Oh S
    Leuk Res; 2017 Sep; 60():103-108. PubMed ID: 28772205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
    Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
    van de Donk NW; Lokhorst HM; Bloem AC
    Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.
    van de Donk NW; Bloem AC; van der Spek E; Lokhorst HM
    Curr Pharm Des; 2006; 12(3):327-40. PubMed ID: 16454747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
    Vrábel D; Pour L; Ševčíková S
    Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.